Form 4 for ABCL AbCellera Biologics Inc.

Accepted 2021-09-15 00:00:00 ET · period of report 2021-09-13 · accession 0001209191-21-056163 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2021-09-15	2021-09-13	ABCL	Hayden Michael R	Dir	M - OptEx	$17.73	+270.0K	1.27M	+27%	+$4.79M
DI	2021-09-15	2021-09-13	ABCL	Hayden Michael R	Dir	M - OptEx	$0.00	+270.0K	270.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2021-09-13	M	A	270,000	$17.73	1,273,397	I See footnote	—	—	(F1) These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.
2	Derivative	Share option (right to buy)	2021-09-13	M	A	270,000	$0.00	270,000	I See footnote	$0.32 · — to 2029-09-11	270,000 Common Shares	(F1) These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein. (F2) Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.32:USD $1.00 for September 11, 2019 as set forth on Bloomberg. (F3) The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on September 11, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.